CR20190273A - Anticuerpos y polipéptidos dirigidos contra cd127 - Google Patents
Anticuerpos y polipéptidos dirigidos contra cd127Info
- Publication number
- CR20190273A CR20190273A CR20190273A CR20190273A CR20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- directed against
- therapeutic
- applications
- polypeptides directed
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 abstract 6
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 108010038498 Interleukin-7 Receptors Proteins 0.000 abstract 2
- 102000010782 Interleukin-7 Receptors Human genes 0.000 abstract 2
- 102000049284 human IL7R Human genes 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se encuentra el campo de los anticuerpos útiles en aplicaciones terapéuticas y de diagnóstico con diana en CD127, la cadena alfa del receptor de IL7, y provee en particular, anticuerpos monoclonales humanizados contra CD127, particularmente CD127 humano, sus usos terapéuticos y aplicaciones de tipo diagnóstico.The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306655 | 2016-12-09 | ||
PCT/EP2017/081911 WO2018104483A1 (en) | 2016-12-09 | 2017-12-07 | Antibodies and polypeptides directed against cd127 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190273A true CR20190273A (es) | 2019-10-17 |
Family
ID=57796143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190273A CR20190273A (es) | 2016-12-09 | 2017-12-07 | Anticuerpos y polipéptidos dirigidos contra cd127 |
Country Status (37)
Country | Link |
---|---|
US (2) | US11098128B2 (es) |
EP (1) | EP3551664B1 (es) |
JP (1) | JP6986559B2 (es) |
KR (1) | KR102306366B1 (es) |
CN (1) | CN110392695B (es) |
AR (1) | AR110326A1 (es) |
AU (1) | AU2017373819B2 (es) |
BR (1) | BR112019010595A2 (es) |
CA (1) | CA3042582C (es) |
CL (1) | CL2019001530A1 (es) |
CO (1) | CO2019005909A2 (es) |
CR (1) | CR20190273A (es) |
CY (1) | CY1124153T1 (es) |
DK (1) | DK3551664T3 (es) |
EA (1) | EA201991005A1 (es) |
ES (1) | ES2867900T3 (es) |
HR (1) | HRP20210697T1 (es) |
HU (1) | HUE054206T2 (es) |
IL (1) | IL266837B (es) |
LT (1) | LT3551664T (es) |
MA (1) | MA49727B1 (es) |
MD (1) | MD3551664T2 (es) |
MX (1) | MX2019006577A (es) |
MY (1) | MY190770A (es) |
NZ (1) | NZ753213A (es) |
PE (1) | PE20191152A1 (es) |
PH (1) | PH12019501285A1 (es) |
PL (1) | PL3551664T3 (es) |
PT (1) | PT3551664T (es) |
RS (1) | RS61808B1 (es) |
RU (1) | RU2769352C2 (es) |
SA (1) | SA519401906B1 (es) |
SI (1) | SI3551664T1 (es) |
TW (1) | TWI777996B (es) |
UA (1) | UA126386C2 (es) |
UY (1) | UY37511A (es) |
WO (1) | WO2018104483A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020525758A (ja) | 2017-06-04 | 2020-08-27 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズRappaport Family Institute for Research in the Medical Sciences | 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット |
JP7285936B2 (ja) * | 2019-01-22 | 2023-06-02 | ブリストル-マイヤーズ スクイブ カンパニー | Il-7rアルファサブユニットに対する抗体及びその使用 |
WO2020254827A1 (en) * | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
CN114514243A (zh) | 2019-06-21 | 2022-05-17 | 索瑞索制药公司 | 多肽 |
BR112022008744A2 (pt) | 2019-11-05 | 2022-07-19 | Medikine Inc | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico |
CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
TW202342505A (zh) * | 2020-02-03 | 2023-11-01 | 美商麥地金公司 | IL-7Rαγc結合化合物 |
US20220389104A1 (en) | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
CN113501499A (zh) * | 2021-08-11 | 2021-10-15 | 无锡贝塔医药科技有限公司 | 一种高纯无水溴化氘气体的制备方法及其应用 |
WO2023232826A1 (en) | 2022-05-30 | 2023-12-07 | Ose Immunotherapeutics | Biomarkers of il7r modulator activity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32038A (es) * | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
UA104663C2 (en) * | 2010-01-28 | 2014-02-25 | Глаксо Груп Лимитед | Antibody binding to cd127 |
TWI552760B (zh) * | 2010-02-24 | 2016-10-11 | 雷那特神經科學股份有限公司 | 拮抗劑抗-il-7受體抗體及方法 |
EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2017
- 2017-12-07 US US16/467,284 patent/US11098128B2/en active Active
- 2017-12-07 CN CN201780076086.8A patent/CN110392695B/zh active Active
- 2017-12-07 HU HUE17835592A patent/HUE054206T2/hu unknown
- 2017-12-07 DK DK17835592.1T patent/DK3551664T3/da active
- 2017-12-07 MD MDE20191173T patent/MD3551664T2/ro unknown
- 2017-12-07 MY MYPI2019003245A patent/MY190770A/en unknown
- 2017-12-07 AR ARP170103427A patent/AR110326A1/es unknown
- 2017-12-07 RU RU2019115610A patent/RU2769352C2/ru active
- 2017-12-07 SI SI201730717T patent/SI3551664T1/sl unknown
- 2017-12-07 EP EP17835592.1A patent/EP3551664B1/en active Active
- 2017-12-07 CR CR20190273A patent/CR20190273A/es unknown
- 2017-12-07 PL PL17835592T patent/PL3551664T3/pl unknown
- 2017-12-07 UA UAA201905605A patent/UA126386C2/uk unknown
- 2017-12-07 JP JP2019530803A patent/JP6986559B2/ja active Active
- 2017-12-07 RS RS20210520A patent/RS61808B1/sr unknown
- 2017-12-07 CA CA3042582A patent/CA3042582C/en active Active
- 2017-12-07 PT PT178355921T patent/PT3551664T/pt unknown
- 2017-12-07 EA EA201991005A patent/EA201991005A1/ru unknown
- 2017-12-07 AU AU2017373819A patent/AU2017373819B2/en active Active
- 2017-12-07 UY UY0001037511A patent/UY37511A/es unknown
- 2017-12-07 KR KR1020197019889A patent/KR102306366B1/ko active IP Right Grant
- 2017-12-07 LT LTEP17835592.1T patent/LT3551664T/lt unknown
- 2017-12-07 WO PCT/EP2017/081911 patent/WO2018104483A1/en active Search and Examination
- 2017-12-07 MX MX2019006577A patent/MX2019006577A/es unknown
- 2017-12-07 MA MA49727A patent/MA49727B1/fr unknown
- 2017-12-07 BR BR112019010595A patent/BR112019010595A2/pt unknown
- 2017-12-07 TW TW106142933A patent/TWI777996B/zh active
- 2017-12-07 ES ES17835592T patent/ES2867900T3/es active Active
- 2017-12-07 PE PE2019001201A patent/PE20191152A1/es unknown
- 2017-12-07 NZ NZ753213A patent/NZ753213A/en unknown
-
2019
- 2019-05-23 IL IL266837A patent/IL266837B/en active IP Right Grant
- 2019-05-30 SA SA519401906A patent/SA519401906B1/ar unknown
- 2019-06-05 CL CL2019001530A patent/CL2019001530A1/es unknown
- 2019-06-05 CO CONC2019/0005909A patent/CO2019005909A2/es unknown
- 2019-06-07 PH PH12019501285A patent/PH12019501285A1/en unknown
-
2021
- 2021-05-05 HR HRP20210697TT patent/HRP20210697T1/hr unknown
- 2021-05-07 CY CY20211100394T patent/CY1124153T1/el unknown
- 2021-06-30 US US17/363,260 patent/US11926671B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20190273A (es) | Anticuerpos y polipéptidos dirigidos contra cd127 | |
ECSP18040758A (es) | Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos | |
EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 | |
CO2020013392A2 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
CL2017000885A1 (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos | |
CL2017001090A1 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
CL2016001716A1 (es) | Anticuerpo moléculas de tim-3 y usos de los mismos | |
CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
CL2018000728A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
PE20170441A1 (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos | |
CO2020014345A2 (es) | Anticuerpos específicos para gucy2c y sus usos | |
CO2017001191A2 (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
CL2016002247A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
ECSP17003946A (es) | Anticuerpos antagonistas del interferón alfa y omega | |
CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. | |
ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos | |
IT201700115761A1 (it) | Bioreattore per la ricellularizzazione e la stimolazione meccanica del diaframma | |
EA201990493A1 (ru) | Антитела к гм-ксф и их применения | |
AR119973A1 (es) | Composiciones y métodos de anticuerpos anti-cd39 | |
AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
EA201990824A1 (ru) | Антитела, которые связываются с интерлейкином-2, и их применение | |
CL2017003020A1 (es) | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos | |
CL2017001172A1 (es) | Anticuerpos anti-interleukin-33 y sus usos |